8-K ·Filed May 8, 2026

NUS

NU SKIN ENTERPRISES, INC.
NEUTRAL
Impact 2/10
Horizondays Processed4mo ago SEC0001140361-26-020028
8-K context-dependent: Items 5.02
Actionable Insight • Neutral

Monitor for announcement of a permanent Chief Product Officer replacement and any potential restructuring or strategic shifts in product leadership. The retention of Mr. Hatchett as an advisor suggests continuity, but absence of a named successor may introduce near-term uncertainty.

DirectionNeutral
Confidencehigh
Horizondays
Final — all horizons settled through T+60d ⚠ clustered
NUS ▼ -21.27% at T+60d
NEUTRAL call ✗ call lost -21.27% · α vs SPY -25.66% · entry $6.63 → $5.22
Entry anchored
May 8, 2026
via day open
T+1d
-1.21%
call -1.21% · α -1.07%
$6.55
settled 5mo ago
T+5d
-11.61%
call -11.61% · α -11.53%
$5.86
settled 5mo ago
T+20d
-17.95%
call -17.95% · α -17.64%
$5.44
settled 4mo ago
T+60d
-21.27%
call -21.27% · α -25.66%
$5.22
settled 8w ago

Price Chart

Loading chart...

Executive Summary

Nu Skin Enterprises disclosed the resignation of EVP and Chief Product Officer Steven K. Hatchett due to family health circumstances, effective May 8, 2026. Mr. Hatchett will continue as a strategic product advisor at an annual salary of $147,478. The departure of a non-CEO executive with a retained advisory role is routine and does not signal operational disruption.

Key Facts

  • Steven K. Hatchett resigned as EVP and Chief Product Officer effective May 8, 2026.
  • Resignation due to family health circumstances.
  • Hatchett will remain as a strategic product advisor with an annual salary of $147,478.
  • No replacement named for the Chief Product Officer role.

Financial Impact

No material financial impact; advisory salary of $147,478 is insignificant relative to company size.

Risk Factors

  • Potential leadership gap if a successor is not identified promptly.
  • Further executive departures could signal broader organizational issues.

Market Snapshot

Exchange
NYSE
Sector
Wholesale-Drugs, Proprietaries & Druggists' Sundries
Analyst Consensus
0% bullish (8 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001140361-26-020028
Document: 0001140361-26-020028-index-headers.html0001140361-26-020028
Document: 0001140361-26-020028-index.html0001140361-26-020028
Document: 0001140361-26-020028.txt0001140361-26-020028
4 reports for NUS
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for NUS — sortable, filterable
TypeNow
Aug 10, 2026
7w ago
8-K
BEARISH ★ 7/10
$4.87 $4.85▲ +0.41%▼ −0.65%$4.61 (+5.34%)
Jun 12, 2026
16w ago
Institutional Cluster
BEARISH ★ 5/10
$5.47 $5.23▲ +4.39%▲ +6.17%$4.61 (+15.72%)
May 8, 2026
21w ago
8-K
NEUTRAL ★ 2/10
$6.63 $5.44▼ −17.95%▼ −17.64%$4.61 (−30.47%)
Apr 3, 2026
26w ago
DEFA14A
NEUTRAL ★ 3/10
$7.52 $7.05▼ −6.25%▼ −15.23%$4.61 (−38.70%)
Showing 4 of 4

US Market Status

Market Closed — Opens Mon (34h 6m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access